Anti-infective therapy for infections caused by drug-resistant gram-negative pathogens now in Phase I study – Outbreak News Today – Outbreak News Today

By NewsDesk  @infectiousdiseasenews
Biopharmaceutical company, Qpex Biopharma, announced this week the initiation of a Phase 1 study of QPX9003, a next generation intravenous (IV)-administered synthetic polymyxin for infections caused by drug-resistant…

Click here to view the original article.